Listen
CASODEX
-
Opinions on drugs -
Posted on
May 31 2006
- Updated on
Aug 14 2006
Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals and various public services
-
Clinical Benefit
| Substantial |
The Actual Benefit of Casodex is substantial. |
Clinical Added Value
| no clinical added value |
Casodex (50 mg, 150 mg) does not provide any improvement in Actual Benefit (level V) in the current management of patients with nonmetastatic prostate cancer at a locally advanced stage, as adjuvant therapy to radical prostatectomy or radiotherapy. |
Contact Us
Évaluation des médicaments
